Bayer
EID Parry acquires Bayer’s nutraceuticals arm Alimtec in Chlie
26 Apr 2014
Alimtec makes Haematococcus pluvialis biomass, a cultured micro-algae, which is a rich natural source of Astaxanthin for human use
Delhi HC bars export of Natco's generic cancer drug on Bayer’s plea
27 Mar 2014
Bayer, in its petition, has pointed out that the generic drug being made under compulsory licence is for sale in India and, thus, cannot be exported
Bayer close to bagging cancer drug maker Algeta for $2.9-bn
24 Feb 2014
German healthcare major Bayer AG today said that it is close to completing its $2.9-billion acquisition of Algeta, after 92.17 per cent shareholders of the Norwegian cancer drug maker tendered their shares to the offer
Bayer, Novartis, Reckitt Benckiser, P&G in fray for Merck & Co's consumer healthcare unit
20 Feb 2014
Bayer, Novartis, Reckitt Benckiser, and Procter & Gamble are among the companies that are exploring a deal to buy Merck &Co's consumer healthcare unit
Bayer to acquire cancer drug maker Algeta
19 Dec 2013
Bayer and Algeta are partners in the sale of the prostate cancer drug Xofigo, which the US FDA had approved in May
EU restrict pesticides use to protect bees
25 May 2013
Bayer loses cancer drug patent case
04 Mar 2013
The ruling ensures that cancer patients would be able to buy generic Nexavar at Rs8,800 for a month’s dose against Rs2,80,000 for Bayer’s branded Nexavar
Bayer clinches deal for sale of Thane land
30 Nov 2012
Bayer backs out from bidding war with Reckitt Benckiser over US vitamins maker Schiff Nutrition
20 Nov 2012
Piramal Healthcare buys Bayer’s molecular imaging and research portfolio
16 Apr 2012
The acquisition includes Florbetaben, a drug candidate for diagnosis of Alzheimer’s disease that is in the final stages of clinical trials, with potential to generate annual revenues of $1.5 billion
Natco granted compulsory licence for Bayer's Nexavar
12 Mar 2012
The compulsory licence, the first of its kind to be granted in India, enables Natco to sell the drug at up to Rs8,880 for a pack of 120 tablets against Rs284,428 for Bayer's Nexavar
Bayer to invest €1 bn in five projects in China
09 Dec 2010
SC rejects Bayer plea against generic Cipla drug
02 Dec 2010
Featured articles
The remarkable Ratan Tata
By Kiron Kasbekar | 23 Oct 2024
One newspaper report of Ratan Tata’s passing away showed an old photo of him climbing into the cockpit of a Lockheed Martin F-16 fighter.
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
